Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALKEM.NS
BuyPremium GrowerAlkem Laboratories Limited · Healthcare · India · $6.5B · Avg Vol: $7M/d
69
StockRankGet insider-trade alerts
Q
72
V
36
M
56
P/E (TTM)
28.5x
ROE
16.7%
D/E
0.1x
Dividend %
1.0%
COMPANY DESCRIPTION
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.4B | 124.4B | 128.0B | 145.3B | 8.3% | 151.3B | 165.0B | 183.4B | 12.4% |
| EPS (INR) | 82.31 | 150.19 | 181.11 | 192.51 | 32.7% | 180.92 | 179.57 | 210.19 | 4.5% |
| Shares | 119.6M | 119.6M | 119.6M | 119.6M | 0.0% | 119.6M | — | — | — |
| Debt | 14.0B | 14.2B | 13.8B | 20.5B | 13.6% | 20.5B | — | — | — |
| Equity | 90.5B | 103.1B | 119.8B | 138.2B | 15.2% | — | — | — | — |
| Op CF | 16.8B | 19.5B | 19.1B | 19.6B | 5.3% | 19.7B | — | — | — |
| Inv CF | 1.1B | -10.1B | -13.0B | -16.7B | — | — | — | — | — |
| Fin CF | -17.6B | -11.5B | -8.1B | -5.0B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-9.2%
SMA 50SMA 200
Close
$53.85
RSI (14)
20.8
52W High
$61.57
From 52W High
0.9%
SCORE BREAKDOWN
Quality
72
ROIC
19.0%89.2
ROE
16.7%84.4
GP/Assets
46.8%84.1
Op. Margin
17.8%79.7
FCF/Assets
6.4%75.8
Piotroski
431.0
Int. Cover
17.2x69.5
D/E Ratio
0.14x56.9
Current Ratio
2.55x49.0
Value
36
P/E (TTM)
28.5x41.8
EV/EBITDA
20.7x33.0
P/FCF
46.2x31.9
P/B
4.4x32.9
P/S
4.1x47.3
Div Yield
1.0%29.6
Momentum
56
52W High %
87%79.6
RS 6M
-4%60.0
SMA 50/200
1.00x57.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+24%37.3
Q Growth
-22%21.9
FUNDAMENTALS
Market Cap
$6.5B
P/E (Forward)
23.0x
Gross Margin
64.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALKEM.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALKEM.NS | Alkem Laboratories Limited(you) | $6.5B | 69 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 78 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| NEULANDLAB.NS | Neuland Laboratories Limited | $3.2B | 64 | Hold |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%